Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapeutic innovation.

T Henkel1

  • 1Molecular Cardiology Division, MediGene AG, Lochhamei Strasse 11, D-82152 Martinsried, Germany. henkel@medigene.de

Idrugs : the Investigational Drugs Journal
|September 13, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Infection rate and complications after 621 transperineal MRI-TRUS fusion biopsies in local anesthesia without standard antibiotic prophylaxis.

World journal of urology·2021
Same author

[Focal therapy of prostate cancer].

Der Urologe. Ausg. A·2017
Same author

[MRI/TRUS fusion-guided prostate biopsy : Value in the context of focal therapy].

Der Urologe. Ausg. A·2016
Same author

Identification of Shell Colour Pigments in Marine Snails Clanculus pharaonius and C. margaritarius (Trochoidea; Gastropoda).

PloS one·2016
Same author

Why we should not routinely apply irreversible electroporation as an alternative curative treatment modality for localized prostate cancer at this stage.

World journal of urology·2016
Same author

[Focal therapy for small renal masses : Observation, ablation or surgery].

Der Urologe. Ausg. A·2016
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

This meeting highlighted novel R&D for cardiovascular diseases, focusing on vascular and cardiac targets. Innovations included small molecules, biologics, gene therapy, vaccines, and diagnostics for conditions like thrombosis and heart failure.

Area of Science:

  • Cardiovascular Research
  • Drug Discovery and Development
  • Biotechnology

Background:

  • Cardiovascular diseases (CVDs) remain a leading cause of mortality globally.
  • Current research focuses on identifying novel therapeutic targets and developing innovative treatments.
  • Collaboration between academia and industry is crucial for advancing cardiovascular R&D.

Purpose of the Study:

  • To provide an overview of current research and development (R&D) approaches in cardiovascular disease.
  • To showcase novel therapeutic strategies and technologies targeting vascular and cardiac conditions.
  • To facilitate knowledge exchange among experts from academia and the biopharmaceutical industry.

Main Methods:

  • Presentation of R&D approaches by delegates from academia and industry.

Related Experiment Videos

  • Focus on therapeutic targets in vasculature (e.g., thrombosis, atherosclerosis, hypertension) and cardiac conditions (e.g., congestive heart failure, arrhythmia).
  • Discussion of diverse technologies including small molecules, protein drugs, gene therapeutics, vaccines, and diagnostic tools.

    • Main Results:

    • Small biopharmaceutical companies presented numerous novel therapeutic approaches.
    • Key indications addressed include thrombosis, atherosclerosis, hyperlipidemia, hypertension, congestive heart failure, and atrial arrhythmia.
    • Innovative diagnostic products for thrombosis and stroke-related brain injury were also featured.

    Conclusions:

    • The meeting underscored the dynamic R&D landscape in cardiovascular disease.
    • A range of therapeutic modalities and targets are being explored for various cardiovascular conditions.
    • Advancements in diagnostics complement therapeutic development for improved patient outcomes.